Identification by high-throughput imaging of the histone methyltransferase EHMT2 as an epigenetic regulator of VEGFA alternative splicing

被引:39
|
作者
Salton, Maayan [1 ]
Voss, Ty C. [1 ]
Misteli, Tom [1 ]
机构
[1] NCI, NIH, Bethesda, MD 20892 USA
基金
美国国家卫生研究院;
关键词
ENDOTHELIAL GROWTH-FACTOR; LYSINE; 9; HUMAN TRANSCRIPTOME; GENE-EXPRESSION; HP1; PROTEINS; CANCER CELLS; IN-VIVO; METHYLATION; H3; G9A;
D O I
10.1093/nar/gku1226
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Recent evidence points to a role of chromatin in regulation of alternative pre-mRNA splicing (AS). In order to identify novel chromatin regulators of AS, we screened an RNAi library of chromatin proteins using a cell-based high-throughput in vivo assay. We identified a set of chromatin proteins that regulate AS. Using simultaneous genome-wide expression and AS analysis, we demonstrate distinct and non-overlapping functions of these chromatin modifiers on transcription and AS. Detailed mechanistic characterization of one dual function chromatin modifier, the H3K9 methyltransferase EHMT2 (G9a), identified VEGFA as a major chromatin-mediated AS target. Silencing of EHMT2, or its heterodimer partner EHMT1, affects AS by promoting exclusion of VEGFA exon 6a, but does not alter total VEGFA mRNA levels. The epigenetic regulatory mechanism of AS by EHMT2 involves an adaptor system consisting of the chromatin modulator HP1 gamma, which binds methylated H3K9 and recruits splicing regulator SRSF1. The epigenetic regulation of VEGFA is physiologically relevant since EHMT2 is transcriptionally induced in response to hypoxia and triggers concomitant changes in AS of VEGFA. These results characterize a novel epigenetic regulatory mechanism of AS and they demonstrate separate roles of epigenetic modifiers in transcription and alternative splicing.
引用
收藏
页码:13662 / 13673
页数:12
相关论文
共 11 条
  • [1] EPIGENETIC SILENCING OF 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE BY HISTONE METHYLTRANSFERASE EHMT2/G9a IN CHOLANGIOCARCINOMA
    Zhang, Jinqiang
    Chen, Weina
    Ma, Wenbo
    Han, Chang
    Wu, Tong
    HEPATOLOGY, 2021, 74 : 688A - 688A
  • [2] Epigenetic Silencing of 15-Hydroxyprostaglandin Dehydrogenase by Histone Methyltransferase EHMT2/G9a in Cholangiocarcinoma
    Zhang, Jinqiang
    Chen, Weina
    Ma, Wenbo
    Song, Kyoungsub
    Lee, Sean
    Han, Chang
    Wu, Tong
    MOLECULAR CANCER RESEARCH, 2022, 20 (03) : 350 - 360
  • [3] IRAS: High-Throughput Identification of Novel Alternative Splicing Regulators
    Zheng, S.
    VISUALIZING RNA DYNAMICS IN THE CELL, 2016, 572 : 269 - 289
  • [4] Integration of ligand and structure-based pharmacophore screening for the identification of novel natural leads against Euchromatic histone lysine methyltransferase 2 (EHMT2/G9a)
    Jana, Abhisek
    Naga, Rahul
    Saha, Sougata
    Grinan-Ferre, Christian
    Banerjee, Deb Ranjan
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2024, 42 (07): : 3535 - 3562
  • [5] Novel alternative splicing isoform biomarkers identification from high-throughput plasma proteomics profiling of breast cancer
    Zhang, Fan
    Wang, Mu
    Michael, Tran
    Drabier, Renee
    BMC SYSTEMS BIOLOGY, 2013, 7
  • [6] Identification of Inhibitors of ABCG2 by a Bioluminescence Imaging-Based High-Throughput Assay
    Zhang, Yimao
    Byun, Youngjoo
    Ren, Yunzhao R.
    Liu, Jun O.
    Laterra, John
    Pomper, Martin G.
    CANCER RESEARCH, 2009, 69 (14) : 5867 - 5875
  • [7] Detection of an Epigenetic Regulator/Histone Methyltransferase and Putative Oncoprotein MMSET/NSD2 Expression in High Grade B-Cell Lymphomas
    Chen, M.
    Zou, J. X.
    Wang, J.
    Chen, H.
    MODERN PATHOLOGY, 2014, 27 : 341A - 342A
  • [8] Detection of an Epigenetic Regulator/Histone Methyltransferase and putative Oncoprotein MMSET/NSD2 Expression in High Grade B-Cell Lymphomas
    Chen, M.
    Zou, J. X.
    Wang, J.
    Chen, H.
    LABORATORY INVESTIGATION, 2014, 94 : 341A - 342A
  • [9] High-throughput screening with nucleosome substrate identifies small-molecule inhibitors of the human histone lysine methyltransferase NSD2
    Coussens, Nathan P.
    Kales, Stephen C.
    Henderson, Mark J.
    Lee, Olivia W.
    Horiuchi, Kurumi Y.
    Wang, Yuren
    Chen, Qing
    Kuznetsova, Ekaterina
    Wu, Jianghong
    Chakka, Sirisha
    Cheff, Dorian M.
    Cheng, Ken Chih-Chien
    Shinn, Paul
    Brimacombe, Kyle R.
    Shen, Min
    Simeonov, Anton
    Lal-Nag, Madhu
    Ma, Haiching
    Jadhav, Ajit
    Hall, Matthew D.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2018, 293 (35) : 13750 - 13765
  • [10] Reawakening of Human Fetal Hemoglobin and an Epigenetic Path to the Clinic for Sickle Cell Disease and Beta-Thalassemia: Identification of an Orally-Available, Potent, and Selective Euchromatic Histone Lysine Methyltransferase 1 and 2 ( EHMT1/2) Inhibitor
    Chan-Penebre, Elayne
    Gibaja, Veronica
    Campbell, John
    Olu, Ogunbodede
    Admirand, Elizabeth
    Brach, Dorothy
    Tang, Cuyue
    Raimondi, Alejandra
    Hood, Tami
    Cocozaki, Alexis
    Karaman, Sule
    Stickland, Kimberly
    Plescia, Christopher
    Munchhof, Michael
    Armstrong, Kelli
    Riera, Thomas
    Orkin, Stuart
    Boriack-Sjodin, Ann
    Janzen, William
    Blakemore, Stephen
    Ribich, Scott A.
    Chesworth, Richard
    Smith, Jesse J.
    Duncan, Kenneth W.
    BLOOD, 2017, 130